Markus Enzelberger

What they invest in

Alexander [name locked], Ph.D., is a Managing Director at Versant Ventures and the head of Ridgeline Therapeutics, the Basel-based Discovery Engine of Versant. He excels in drug discovery and medicinal chemistry, drawing on his experience at Roche Pharma Research. [name locked]'s investment focus areas at Versant Ventures are in early biotech investment and company creation, with a keen interest in sourcing innovative opportunities globally within the healthcare industry. His geographical preference spans Europe, the U.S., and Asia. Since 2016, Alexander has been involved in launching and investing in companies like Black Diamond, Monte Rosa, Bright Peak, Enterprise, T-knife, and Matterhorn. With a Ph.D. in organic chemistry from Oxford University, Alexander brings deep operating capabilities and a strong track record to his role, reflecting his commitment to fostering partnerships and collaborations within the industry.

Who works there

20 people on file: 20 with an email address, 20 with a phone number, 19 with a professional profile. Names and details are behind a free account.

No card. Each contact is charged once and stays yours.